Latest & greatest articles for statin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on statin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on statin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for statin

121. Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Subjects Receiving Antiretroviral Therapy Full Text available with Trip Pro

Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Subjects Receiving Antiretroviral Therapy Human immunodeficiency virus (HIV)-infected individuals are at increased risk of cardiovascular disease (CVD) due in part to inflammation. Statins decrease inflammation in the general population, but their effect during HIV infection is largely unknown.This is an ongoing randomized, double-blinded, placebo-controlled trial to evaluate the effect of statin therapy (...) in the statin group, compared with an increase in the placebo group (-28% vs +3.8%; P < .01). A 10% reduction in the lipoprotein-associated phospholipase A2 (Lp-PLA2) level was seen in the statin group, compared with a 2% reduction in the placebo group (P < .01). In multivariable regression, receipt of statin treatment and having a nadir CD4(+) T-cell count of ≤100 cell/µL were the only statistically significant predictors of a decrease in Lp-PLA2 level. Markers of systemic inflammation did not change

2014 EvidenceUpdates Controlled trial quality: predicted high

122. Statins have no side effects? What our study really found, its fixable flaws, and why trials transparency matters (again).

and bladder, I did not know my wife, nor 2 year old son, I was evaluated by evert Neurologist on Staff, Many residents, and Med Students…all of which had a range of possible diagnosis, from New Variant Cruetzfeld Jakob Disease, Mitochondrail disorders, Alzheimers, Variant MS etc…not one of these ever suspected a Chemical Cause…Such as the one that blocks HMG CoA reductase enzyme production…I remember when I worked in the Emergency Room, there was a doctor I worked with, who when faced with a difficult (...) Statins have no side effects? What our study really found, its fixable flaws, and why trials transparency matters (again). Statins have no side effects? What our study really found, its fixable flaws, and why trials transparency matters (again). – Bad Science Search TED Talk Collected Journalism This Nerdy Book This Great Book T-shirts Categories (3) (4) (6) (45) (28) (6) (16) (190) (5) (20) (52) (88) (2) (1) (2) (1) (677) (4) (14) (2) (37) (4) (9) (3) (11) (6) (3) (16) (13) (1) (6) (8) (6) (6

2014 Bad Science

123. Statins

Statins USE OF STATINS IN PREGNANCY 0344 892 0909 USE OF STATINS IN PREGNANCY (Date of issue: March 2017 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin and simvastatin) are a class of HMG-CoA reductase inhibitors used to lower (...) cholesterol. They act by inhibiting the conversion of HMG-CoA to mevalonate which is a rate-limiting step in the production of cholesterol in the liver. Statins may be indicated, as an adjunct to diet, for the treatment of primary hypercholesterolaemia or mixed dyslipidaemia when non-pharmacological treatments (e.g. diet, exercise, weight reduction) are inadequate, or for reduction of cardiovascular morbidity and mortality in manifest atherosclerotic cardiovascular disease or diabetes mellitus

2014 UK Teratology Information Service

124. IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin?

IMPROVE-IT - To add, or not to add ezetimibe EZETROL to moderate dose statin? RxFiles: Trial Summary www.RxFiles.ca - Dec 2014, Updated June 2015 Loren Regier BSP BA, Brent Jensen BSP IMPROVE-IT To add, or not to add ezetimibe EZETROL to moderate dose statin? What we already knew? ? Statins… have consistently demonstrated efficacy in lowering not only LDL, but risk of cardiovascular (CV) events +/- mortality in those with high CV risk. 1 ? Ezetimibe… 2 o has no evidence as monotherapy (...) for lowering CV/mortality risk o has had very limited, disappointing surrogate outcome evidence, e.g. no ? in intima -media thickness ENHANCE o failed to lower CV/mortality risk in combination with a statin when compared to a placebo in mild - to -moderate, asymptomatic aortic stenosis patients SEAS o when combined with a proven statin therapy (e.g. simvastatin 20mg daily) in chronic kidney disease & dialysis patients (stage 3 -4 CKD patients), was associated with a benefit. However, given the placebo

2014 RxFiles

125. Taking a statin to reduce the risk of coronary heart disease and stroke

Taking a statin to reduce the risk of coronary heart disease and stroke Statins to reduce the risk of CHD and stroke: patient decision aid Copyright © NICE 2014. All rights reserved. Last updated November 2014 Page 1 of 23 Taking a statin to reduce the risk of coronary heart disease and stroke http://www.nice.org.uk/guidance/cg181/resources/cg181-lipid-modification-update-patient-decision- aid2 Published: November 2014 About this decision aid This decision aid is intended to help you to make up (...) your mind whether or not to take a statin to help reduce your risk of having a heart attack or developing angina (together called coronary heart disease or CHD), or of having a stroke. Your decision depends on several things that this information will help to explain. Different people will feel that some of these things are more important to them than others, so it is important that you make a decision that is right for you. This decision aid is designed for you to work through with the healthcare

2014 Health Information and Quality Authority

126. Statins for cardiovascular disease

Statins for cardiovascular disease Probabilities of benefits and harms Patient preferences DECISION Later Yes No Questions to identify the patient's decision making needs: ? Do you have any questions about the benefits and harms of each option? ? Which benefits and harms matter most to you? ? Who will support and advise you in making a choice? ? Do you feel sure about the best choice for you? Presenting statins to patients What are statins for? Statins are medications taken daily to reduce (...) the concentrations of cholesterol in the blood and reduce the risks of having cardiovascular (CV) or cerebrosvascular (CeV) events. Among individuals who have never had cardiovascular disease (primary prevention), who might consider using statins? ? Adults at moderate to high risk of developing cardiovascular disease in the next 10 years. The probability of having a CV event in the next 10 years is evaluated using a risk calculator such as the Framingham Cardiac Risk Score* taking into account sex, age, diabetes

2014 Cancer Council Australia

127. Observational study: New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment

Observational study: New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here New ACC-AHA cholesterol guidelines significantly increase potential eligibility for statin treatment Article Text Practice guideline Observational study New ACC-AHA

2014 Evidence-Based Medicine

128. Diagnosis, prevention, and management of statin adverse effects and intolerance

Diagnosis, prevention, and management of statin adverse effects and intolerance Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update - Canadian Journal of Cardiology Email/Username: Password: Remember me Search Terms Search within Search Share this page Volume 29, Issue 12, Pages 1553–1568 Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update x G.B. John Mancini (...) text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Abstract The Proceedings of a Canadian Working Group Consensus Conference, first published in 2011, provided a summary of statin-associated adverse effects and intolerance and management suggestions. In this update, new clinical studies identified since then that provide further insight into effects on muscle, cognition, cataracts, diabetes, kidney disease, and cancer are discussed. Of these, the arenas

2014 CPG Infobase

129. Statins benefits and risks

Statins benefits and risks Statins: benefits and risks - GOV.UK GOV.UK uses cookies to make the site simpler. or Search Statins: benefits and risks Statins (HMG-CoA reductase inhibitors) are widely used medicines for patients with lipid disorders and in the primary and secondary prevention of heart attack and stroke. Published 11 December 2014 From: Therapeutic area: Contents Article date: May 2014 The statins currently available in the UK are simvastatin, atorvastatin, pravastatin, fluvastatin (...) , and rosuvastatin. Evidence from large clinical trials shows that statins can reduce heart attacks and the need for bypass surgery, and can save lives in certain patient groups. Meta-analysis of randomised trial data shows that if patients with a 10-year cardiovascular risk of at least 20% take statins for 5 years, it would prevent at least 450 heart attacks, strokes, or vascular deaths per 10,000 treated patients. The importance of statin safety data from clinical studies and clinical practice Large clinical

2014 MHRA Drug Safety Update

130. Cohort study: High-potency statins are associated with increased hospitalisations with acute kidney injury Full Text available with Trip Pro

Cohort study: High-potency statins are associated with increased hospitalisations with acute kidney injury High-potency statins are associated with increased hospitalisations with acute kidney injury | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here High-potency statins are associated with increased hospitalisations with acute kidney injury Article Text Aetiology Cohort study High-potency statins are associated with increased

2014 Evidence-Based Medicine

131. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Full Text available with Trip Pro

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy.To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin.Phase 3, 12-week, randomized, double-blind, placebo (...) - and ezetimibe-controlled study conducted between January and December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries.Patients (n = 2067) were randomized to 1 of 24 treatment groups in 2 steps. Patients were initially randomized to a daily, moderate-intensity (atorvastatin [10 mg], simvastatin [40 mg], or rosuvastatin [5 mg]) or high-intensity (atorvastatin [80 mg], rosuvastatin [40 mg]) statin. After a 4-week lipid-stabilization period, patients (n

2014 JAMA Controlled trial quality: predicted high

132. Systematic review and meta-analysis: Statins do not improve cardiovascular outcomes for dialysis patients

Statistics from Altmetric.com Commentary on: Palmer SC , Navaneethan SD , Craig JC , et al . HMG CoA reductase inhibitors (statins) for dialysis patients: a systematic review and meta-analysis . Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways. Copyright information: Published (...) Systematic review and meta-analysis: Statins do not improve cardiovascular outcomes for dialysis patients Statins do not improve cardiovascular outcomes for dialysis patients | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers

2014 Evidence-Based Medicine

133. Cohort study: Statin potency associated with incident diabetes in a real-world evaluation

Cohort study: Statin potency associated with incident diabetes in a real-world evaluation Statin potency associated with incident diabetes in a real-world evaluation | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Statin potency associated with incident diabetes in a real-world evaluation Article Text Aetiology Cohort study Statin potency associated with incident diabetes in a real-world evaluation Dylan L Steen , Deepak L Bhatt

2014 Evidence-Based Medicine

134. Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Statin Therapy on Mortality in Patients With Ventilator-Associated Pneumonia: A Randomized Clinical Trial. Observational studies have reported that statin use may be associated with improved outcomes of various infections. Ventilator-associated pneumonia (VAP) is the most common infection in the intensive care unit (ICU) and is associated with substantial mortality.To determine whether statin therapy can decrease day-28 mortality in patients with VAP.Randomized, placebo-controlled (...) for futility at the first scheduled interim analysis after enrollment of 300 patients, of whom all but 7% in the simvastatin group and 11% in the placebo group were naive to statin therapy at ICU admission. Day-28 mortality was not lower in the simvastatin group (21.2% [95% CI, 15.4% to 28.6%) than in the placebo group (15.2% [95% CI, 10.2% to 22.1%]; P = .10; hazard ratio, 1.45 [95% CI, 0.83 to 2.51]); the between-group difference was 6.0% (95% CI, -3.0% to 14.9%). In statin-naive patients, day-28

2013 JAMA Controlled trial quality: predicted high

135. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study Full Text available with Trip Pro

Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study To assess the impact on healthcare resource utilization, costs, and quality of life over 15 years from 5 years of statin use in men without a history of myocardial infarction in the West of Scotland Coronary Prevention Study (WOSCOPS).Six thousand five hundred and ninety-five participants aged 45-54 years were randomized (...) failure and coronary revascularization. There was no excess in non-cardiovascular admissions or costs (or in admissions associated with diabetes or its complications) and no evidence of heterogeneity of effect over sub-groups defined by baseline cardiovascular risk.Five years' primary prevention treatment of middle-aged men with a statin significantly reduces healthcare resource utilization, is cost saving, and increases QALYs. Treatment of even younger, lower risk individuals is likely to be cost

2013 EvidenceUpdates Controlled trial quality: uncertain

136. High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect Full Text available with Trip Pro

High-Dose Statin Therapy in Patients With Stable Coronary Artery Disease: Treating the Right Patients Based on Individualized Prediction of Treatment Effect Clinicians need to identify coronary artery disease patients for whom the benefits of high-dose versus usual-dose statin therapy outweigh potential harm. We therefore aimed to develop and validate a model for prediction of the incremental treatment effect of high-dose statins for individual patients in terms of reduction of 5-year absolute (...) needed to treat was ≥50. A decision curve shows that making treatment decisions on the basis of predictions using our model may improve net benefit.Estimation of the incremental treatment effect of high-dose versus usual-dose statin therapy in individual coronary artery disease patients enables selection of high-risk patients that benefit most from more aggressive therapy.http://www.clinicaltrials.gov. Unique identifiers: NCT00327691 and NCT00159835.

2013 EvidenceUpdates

137. Statins and the risk of interstitial lung disease: a cohort study Full Text available with Trip Pro

Statins and the risk of interstitial lung disease: a cohort study Case reports have suggested that the use of statins may be associated with an increase in the risk of interstitial lung disease (ILD).Within a large cohort of users of respiratory medications identified in the Quebec health administrative databases during 1990-2005, we carried out a nested case-control analysis of the relationship between statins and the risk of ILD as defined by specialist visits or hospitalisations.The cohort (...) included over 1.4 million patients, of which 6665 possible or probable cases of ILD were identified during follow-up. These were compared with 26 660 controls matched for age, gender and calendar time. After adjustment for confounders and comorbid conditions, there was no association between current use of statins and risk of ILD (adjusted OR 0.99, 95% CI 0.91 to 1.08). The results were similar when any use of statins within the previous 1 or 2 years was considered or when the analysis was limited

2013 EvidenceUpdates

138. Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Full Text available with Trip Pro

Statin toxicity from macrolide antibiotic coprescription: a population-based cohort study. Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4.To measure the frequency of statin toxicity after coprescription of a statin with clarithromycin or erythromycin.Population-based cohort study.Ontario, Canada, from 2003 to 2010.Continuous statin users older than 65 (...) years who were prescribed clarithromycin (n = 72,591) or erythromycin (n = 3267) compared with those prescribed azithromycin (n = 68,478).The primary outcome was hospitalization with rhabdomyolysis within 30 days of the antibiotic prescription.Atorvastatin was the most commonly prescribed statin (73%) followed by simvastatin and lovastatin. Compared with azithromycin, coprescription of a statin with clarithromycin or erythromycin was associated with a higher risk for hospitalization

2013 Annals of Internal Medicine

139. Statin use and risk of pancreatic cancer: a meta-analysis

Statin use and risk of pancreatic cancer: a meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.

140. Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus

Meta-analysis of the effects of statin therapy on endothelial function in patients with diabetes mellitus Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2013 DARE.